|Articles|September 1, 2015
Considerations in the Development of Controlled Release Formulations
Author(s)Xcelience, LLC
Related Content
Trending on Pharmaceutical Technology
1
Europe Tried to Ban Generative AI From Critical GMP. The Ban May Not Survive. It Does Not Matter.
2
What Does TAUKLARIFY's Approval Mean for Alzheimer's Drug Developers?
3
Pharma's AI ROI Problem Isn't a Tech Problem but a Qualification Problem
4
Danish Biotechs Attracting Investor Attention
5